Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Birth Control Methods01:22

Birth Control Methods

186
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
186
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment.

Primary care·2026
Same author

Primary Care at the Center of America's Mental Health Landscape.

Primary care·2026
Same author

NMRhub: An NMR Data Ecosystem Spanning the Complete Data Lifecycle.

Journal of molecular biology·2026
Same author

Scalable cyberinfrastructure for experimental NMR data.

Scientific data·2025
Same author

Engaging Burn Survivors, Their Families, and the Burn Community in Patient-Centered Outcomes Research: A Burn Survivor- and Burn Community Stakeholder-Generated and Prioritized Research Agenda.

Journal of burn care & research : official publication of the American Burn Association·2024
Same author

Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec.

JAAD case reports·2024

Related Experiment Video

Updated: Jun 1, 2025

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
05:46

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

9.9K

Keep on Keeping on - Mirena IUD for 8 Years.

Samuel Holt McNair1, Carl Tunink2, Laura Morris1

  • 1From the University of Missouri, Columbia, MO (SHM, CT, LM).

Journal of the American Board of Family Medicine : JABFM
|January 17, 2025
PubMed
Summary

Mirena intrauterine device (IUD) is effective for contraception for up to 8 years. Extended use failure rates from years 6-8 were similar to earlier use periods, confirming its long-term reliability.

Keywords:
52-mg Levonorgestrel releasing intrauterine systemContraceptive effectivenessExcessive uterine bleedingLong-acting reversible contraceptionPearl index

More Related Videos

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
03:30

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy

Published on: October 25, 2024

1.3K
Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse
03:43

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse

Published on: September 13, 2022

5.2K

Related Experiment Videos

Last Updated: Jun 1, 2025

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
05:46

Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation

Published on: January 17, 2019

9.9K
Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
03:30

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy

Published on: October 25, 2024

1.3K
Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse
03:43

Laparoscopic Non-Mesh Cerclage Pectopexy for Pelvic Organ Prolapse

Published on: September 13, 2022

5.2K

Area of Science:

  • Reproductive health
  • Contraception
  • Endocrinology

Background:

  • Levonorgestrel-releasing intrauterine systems (LNG-IUS) are widely used for long-term contraception.
  • Mirena (levonorgestrel-releasing intrauterine system) has been approved for up to 6 years of use.
  • Extended use data is crucial for patient counseling and clinical practice guidelines.

Purpose of the Study:

  • To evaluate the contraceptive effectiveness of the Mirena IUD during extended use up to 8 years.
  • To compare the failure rates during years 6-8 with those of the initial 5 years of use.

Main Methods:

  • Analysis of cumulative failure rates from clinical trials and post-marketing surveillance data.
  • Inclusion of data for users extending IUD use beyond the initially approved 6-year period.

Main Results:

  • The cumulative failure rate for the Mirena IUD from year 6 through year 8 was 0.68%.
  • This failure rate is comparable to the reported cumulative failure rates during the first 5 years of use.
  • No significant increase in failure rates was observed during extended use.

Conclusions:

  • Mirena IUD maintains its contraceptive effectiveness for extended use up to 8 years.
  • Patients can be counseled on the continued reliability of the Mirena IUD for an 8-year duration.
  • The findings support the safety and efficacy of extended use of Mirena for contraception.